Phase I Vaccine Trial Shows Promise for Preventing Triple-Negative Breast CancerPhase I Vaccine Trial Shows Promise for Preventing Triple-Negative Breast Cancer
(MedPage Today) — At the San Antonio Breast Cancer Symposium (SABCS), investigators reported final phase I results of an alpha-lactalbumin (aLA) vaccine designed to help prevent triple-negative breast cancer (TNBC), particularly among women at…
AI Model Improves Prediction of Early and Late Breast Cancer RecurrenceAI Model Improves Prediction of Early and Late Breast Cancer Recurrence
(MedPage Today) — At the San Antonio Breast Cancer Symposium, researchers presented a study on a multimodal artificial intelligence model that integrated clinical data, pathology-based imaging, and expanded molecular profiling to improve prediction…
Sperm donor with rare cancer-causing mutation fathers nearly 200 children across EuropeSperm donor with rare cancer-causing mutation fathers nearly 200 children across Europe
A sperm donor who carried a cancer-causing gene mutation fathered nearly 200 children, an investigation by 14 European news organizations show.
Real-World Outcomes Favor Standard Care in HER2-Positive Metastatic Breast CancerReal-World Outcomes Favor Standard Care in HER2-Positive Metastatic Breast Cancer
(MedPage Today) — At the San Antonio Breast Cancer Symposium (SABCS), a large retrospective analysis of U.S. electronic health records compared outcomes for patients with HER2-positive metastatic breast cancer who received first-line guideline…
Novel endocrine therapy improves disease-free survival over standard of care for patients with early-stage breast cancerNovel endocrine therapy improves disease-free survival over standard of care for patients with early-stage breast cancer
The investigational, oral selective estrogen receptor degrader (SERD) giredestrant given as an adjuvant therapy showed significant improvement in invasive disease-free survival (iDFS) compared with the current standard-of-care endocrine therapy in patients with early-stage, hormone receptor (HR)-positive, HER2-negative breast cancer, according to the results of a Phase III IidERA trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9–12, 2025.
Sacituzumab govitecan-hziy led to similar progression-free survival as standard of care for some breast cancers: TrialSacituzumab govitecan-hziy led to similar progression-free survival as standard of care for some breast cancers: Trial
Patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancers had similar progression-free survival (PFS) whether they were treated with sacituzumab govitecan-hziy (Trodelvy) or standard-of-care chemotherapy as the first treatment after endocrine therapy, according to results from a Phase III ASCENT-07 clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9–12, 2025.
Adding tucatinib to first-line maintenance therapy delays disease progression in HER2-positive metastatic breast cancerAdding tucatinib to first-line maintenance therapy delays disease progression in HER2-positive metastatic breast cancer
Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta) delayed disease progression in patients with HER2-positive metastatic breast cancer, potentially extending time off chemotherapy, according to results from a Phase III clinical trial HER2CLIMB-05 presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9–12, 2025.
Novel endocrine therapy reduces the risk of breast cancer recurrenceNovel endocrine therapy reduces the risk of breast cancer recurrence
In an international study led by UCLA, researchers have shown that giredestrant, a next-generation oral selective estrogen receptor antagonist and degrader (SERD), when given as an adjuvant therapy for early-stage (1–3) hormone receptor (HR)-positive, HER2-negative breast cancer, significantly lowered the risk of the disease returning when compared with standard hormone therapies long considered the backbone of treatment.
Sperm donor with cancer-causing gene fathers nearly 200 children across EuropeSperm donor with cancer-causing gene fathers nearly 200 children across Europe
A genetic mutation that carries a 90% cancer risk has been passed on by an unwitting sperm donor to dozens of children, a Europe-wide investigation has revealed.
New Ozempic-alternative diabetes pill burns fat without muscle loss, study suggestsNew Ozempic-alternative diabetes pill burns fat without muscle loss, study suggests
Scientists in Sweden have created a new pill designed to help the body burn fat and control blood sugar in a different way than popular GLP-1 drugs, like Ozempic. While injectable GLP-1s work by suppressing appetite, this new treatment boosts metabolism in the muscles. A study led by researchers at Karolinska Institutet and Stockholm University Read More